Calls of the Day: Bank of America, Oracle, Abbvie and Pfizer

Hi, welcome back. Let’s do some calls in the day. We’ll start with Bank of America today downgraded to HSBC, that’s to hold from by. Mike Mayo has raised his price target by the way at Wells Securities on Bank of America by 4 bucks to 44. So by the way, it is up 44% as well from the October 27th low. Nobody owns this. You got JPM though, which has been a stalwart. Yeah. I mean, it’s the best, it’s the best of the group on many levels, almost on any time frame that’s like reasonably long enough. The stock has outperformed nothing against Bank of America technically. It actually looks great. And I think a lot of people can make money and a lot of these stocks, the banks have actually been the big laggards amongst the financials. The insurance companies have acted better. We’ve we’ve seen like a lot of outperformance relative to the banks, but now the banks are bringing up the rear and that’s OK. Maybe it’s that time in the cycle for them. So I don’t think you need a rate cut here. I think similar to the rest of the market, the promise of a rate cut is good enough for right now. And these companies, they’ve gotten rid of some competitors, a lot of the the flows of of money have gone their way because they’re considered to be safer and more stable. So they’ve won already on a lot of fronts fundamentally. Now the stocks starting to work. All right. How about Oracle added to the fresh money listed, Deutsche Jimmy Buy 150 is the price target. Yeah, this is, this is a place to put new money right now. If you’re wondering where in the markets you can put new money, this is a place. Now, I’m not saying it can’t go down next week by 3%. If it happens, just leave me alone for the long run. This is a stock that’s trading at about 20 times forward earnings with the sentiment. So both the fundamentals and the sentiment is behind it after their Q3 report, building data centers like crazy to support AI and cloud computing. You know, this is a stock that underperformed technology for the last 15 years and now is rapidly catching up at the very least day out of its way. But if you have money to put to work and technology, this is the place. If it goes down 3% next week, can I give you the business? Oh, I. This is how it works. I give you permission. Is that. Well, you just said if it does leave me alone. I’m like, I mean, I didn’t. I’m not agreeing to anything. I know you’re not. I was just checking what is it opposite day or something? All right. I don’t know. Abby. What about that? JP Morgan reiterates that as overweight. You own that. Yeah, beautiful healthcare stock. They’ve made some key acquisitions. First off, very attractively priced 16 times earnings. It’s got a nice dividend yield. They’ve made some attractive acquisitions right now, a lot of money coming into healthcare space. Again, this is one that you really shouldn’t worry about and if you have new money, you can put it to work here. All right. What about healthcare? Yeah, I mean, yeah, Pfizer, which you know you, you singled out a couple weeks ago. Yeah, look, Healthcare is really multi dimensional. It’s really tough to make a broad call on healthcare, period. It’s not like the energy stocks where they’re unidirectional and mostly behave in line with what the commodity does. In this particular case, you’ve got all different reasons why different sectors might be under or outperforming. I do think broadly the fear over GOP one or the excitement over GOP one, depending on which stock, I think that’s probably been overdone. It’s going to get very competitive. Even if you think it’s a huge business, it’s not a slam dunk to just buy any company that has a drug in development for that space. By the same token, a lot of stocks have been ignored by investors because they’re not working on GOP one drugs or they haven’t gotten far enough. And I think that’s the case with Pfizer. Stock has been left behind by the group, been left behind by the market, one of the worst performing names over the last three years. I don’t think the fundamentals are as bad as where the current valuation is. I’m a buyer here. It doesn’t look like most of the stocks I normally talk about. I usually prefer the 52 week high list. This is on the three-year low list, but I’m in here and I think things could turn in the second-half of the year. Speaking of healthcare, UNH Jimmy that’s let you down, it’s down 6 1/2% year to date. It’s only up 4% / a year. We all know what the market’s done relative to that we do. And there’s two things facing United Healthcare. One is this data breach from a few weeks ago, it’s going to cost them some money now. They’ve already announced town. I think it’s about 3 billion. They’ve already announced it. The market does want to get past that. It wants to get past the second issue, which is medical loss ratios, which are higher than expectations in the upcoming earnings report. And they’re an early reporter. Let’s look at those medical loss ratios. That’s the real story. The data breach is awful, but it’s behind us.